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For over 40 years the Developmental Therapeutics Program (DTP)
of the National Cancer Institute, USA, has been a global resource
for cancer drug developers. Using rodent tumours, then human
tumour xenografts and most recently human tumour cell lines, the
DTP has developed screening systems with the aim of identifying
compounds with potential clinical activity. The tumours and cell
lines in the screens were largely selected because of their sensi-
tivity to known, clinically active, anticancer drugs and results from
the DTP screens have contributed to the development of many of
the cytotoxic drugs in widespread clinical use today. In line
with the vast majority of academic drug development groups and
pharmaceutical companies, the DTP now focuses on mechanism-
based drug discovery, which it is widely anticipated will result in
the identification of compounds with greater activity and anti-
tumour specificity than that seen with cytotoxic drugs. Extensive
experience with anti-endocrine therapy for the treatment of
hormone-dependent tumours, and more recently with trastuzumab
and STI571, for the treatment of C-erbB2 over-expressing breast
cancer and bcr-abl positive leukaemias, respectively, provides
encouragement for target-based drug discovery programmes. 
The move away from screening to mechanism-based approaches
to drug discovery represents a watershed, and an opportunity to
reflect on pre-clinical antitumor models and their utility. The expe-
rience of the NCI DTP and Cancer Therapy Evaluation Programme
(CTEP) is second to none, and the paper by Johnson and colleagues
in this issue has seized this opportunity. In addition to providing a
retrospective analysis of the relative abilities of in vitro cell line,
hollow fibre and xenograft models to predict clinical activity this
paper, as the authors point out, constitutes an important benchmark
against which future results will be measured. Whilst we confi-
dently predict that mechanism-based drug development will out-
perform screening approaches in the discovery of active agents, we
need hard data to show that this is the case and the paper from the
DTP and CTEP provides these data for pre-clinical studies with
conventional cytotoxic drugs. Lastly, even with drugs designed to
exploit cancer-related targets, models are still needed to provide
confidence that clinical activity can be realistically anticipated,
which raises the question of which models to use. With greater
experience, it may one day be possible to move in one step from a
genomic or proteomic analysis of clinical material through drug
design and development to a clinical trial without the use of any
pre-clinical tumour models. However, such a day is still some way
off and Phase I clinicians, regulatory authorities, ethics committees
and patients themselves require reassurance that a new treatment is
likely to be of potential benefit. 
So, what is the best pre-clinical model? Where should the
tumour cells be grown; in tissue culture flasks, intra-peritoneal
hollow fibres or implanted in mice? For 39 agents for which Phase
II data were available, activity in one-third or more of the xeno-
grafts tested was predictive of subsequent Phase II clinical activity.
However, with the exception of non-small cell lung cancer, pre-
clinical xenograft activity in a particular histological type of
cancer was not predictive for the tumour type subsequently found
to be sensitive in patients. Thus, on the basis of these data, the clin-
ical Phase II trial cannot be replaced by a pre-clinical study.
Although the number of different xenografts per histology was
only 7–9, i.e. not the normal Phase II number of 14 tumours, there
were nevertheless enough tumours to be confident that pre-clinical
studies could not be a substitute for clinical trials, within the limi-
tations of acceptable levels of animal usage. 
Given that activity in xenograft models has clinical relevance,
the question of what best predicts xenograft activity becomes an
issue, in order to minimize the number of animals used in such
studies. Overall, 35% of 537 compounds tested had xenograft
activity against at least 1 tumour, and for compounds active in
0–3, 4–6, 7–9 or 10 or more intraperitoneal hollow fibres, the level
of activity was 28%, 34%, 46% and 63%, respectively. Hence the
question becomes whether, or not, improving the likelihood of
selecting a xenograft-active compound from 35% to 63% would
be worth all the hollow fibre studies? A detailed analysis of
numbers of mice used and time required to generate the hollow
fibre and xenograft results would help in answering this question,
and such an analysis should be undertaken to ensure that the
minimum number of experimental animals are being used identify
agents for clinical study. An alternative to the hollow fibre model
is the use of tumour cell lines grown in vitro, which has the advan-
tage of reducing the use of animals still further, relative to the
hollow fibre assay. The authors report the encouraging result that
in vitro activity against 6 or more lung or breast cancer cell lines
does predict xenograft activity against these tumour types.
Furthermore, in vitro tumour type selectivity predicted hollow
fibre tumour type selectivity in 5 histologies, and greater in vitro
potency was a portent of a greater level of activity against hollow
fibres. Lastly, the authors address the issue of whether or not the
chemical structure of the compound can be used to predict activity,
and show that both MW and hydrogen-bonding capability can
influence activity; data which highlights the importance of compu-
tational chemistry in drug design and evaluation. 
In summary, the DTP and their colleagues in CTEP at the NCI
are to be applauded for performing this important analysis. They
have set the benchmark against which the pre-clinical aspects of
mechanism-based drug development can be compared. For
conventional cytotoxic drugs, which constituted the vast majority
of the agents studied by the DTP and CTEP, demonstrating activity
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by activity in the hollow fibre model and in turn in in vitro cell
lines, is of value. Whether this remains the case for the new 
generation of cancer target-specific drugs remains to be seen and a
new experiment, potentially the last, is just beginning. 
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